Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China, has entered into a licensing agreement with fellow Chinese firm Nanjing JSIAMA Biopharmaceutical Co., Ltd. This deal grants Junshi the rights to research and develop, manufacture, file for regulatory approval, commercialize, and hold other interests in JSIAMA’s IAMA-001 nasal spray across Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. Additionally, Junshi secures co-development rights for the product outside of Greater China.
As per the agreement, Junshi will make an upfront payment of RMB 40 million to JSIAMA and is obligated to pay up to RMB 390 million in R&D milestone payments and up to RMB 250 million in sales milestone payments. The agreement also includes a provision for single-digit sales commission. Furthermore, all rights and revenue sharing will be equally divided between the two companies for the development and commercialization of IAMA-001 outside of Greater China.- Flcube.com
